IO Biotech is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines, which suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.
IO Biotech total Funding
IO Biotech latest funding size
Time since last funding
|8 months ago|
IO Biotech investors
|Sunstone Capital, Idinvest Partners, Novo Nordisk, RA Capital Management, Vivo Capital, Novo Seeds, Lundbeckfonden Ventures, Kurma Partners, Lundbeckfonden Emerge, Samsara BioCapital, HBM Healthcare Investments, Sunstone Life Science Ventures, Soleus Capital, Avoro Capital, Eir Ventures, PFM Health Sciences, Serrado Capital|
When was IO Biotech founded?
IO Biotech was founded in 2014.
Who are IO Biotech key executives?
IO Biotech's key executives are Peter Hirth, Mai-Britt Zocca and Emmanuelle Coutanceau.
Who are IO Biotech competitors?
Competitors of IO Biotech include XBiotech, Confo Therapeutics and Rubius Therapeutics.
Where is IO Biotech headquarters?
IO Biotech headquarters is located at 3 Ole Maaløes Vej, København.
Where are IO Biotech offices?
IO Biotech has an office in København.
How many offices does IO Biotech have?
IO Biotech has 1 office.
Receive alerts for 300+ data fields across thousands of companies